Arvinas, Inc.

NASDAQ:ARVN

Biotechnology

Healthcare
$6.77 -1.30%

-$0.10 today

Market cap
$443.01M
Beta
1.75
P/E (TTM)
-2.2
EPS (TTM)
-$3.46
52W Low $6.06High $14.51

Volume 1.09M

Average 0.89M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$273.80M

FY 2025 · Annual

Investing Cash Flow

$407.60M

FY 2025 · Annual

+1074.6% YoY

Financing Cash Flow

-$91.40M

FY 2025 · Annual

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(191M)(282.5M)(367.3M)(198.9M)(80.8M)
Depreciation & Amortization6M8.2M6.7M6.6M5.2M
Deferred Income Tax00000
Stock-Based Compensation57.1M75.5M71.6M88.2M44M
Change in Working Capital678.3M(82.6M)(44.4M)(140.6M)(233.7M)
Accounts Receivables(30.2M)14M800K(5.7M)7.3M
Inventory00000
Accounts Payables27.9M20.2M17.3M(21.2M)(1.7M)
Other Working Capital680.6M(116.8M)(62.5M)(113.7M)(239.3M)
Other Non-Cash Items9M7.9M(14.4M)(14.6M)(8.5M)
Operating Cash Flow559.4M(273.5M)(347.8M)(259.3M)(273.8M)
Capital Expenditures(4.7M)(6.8M)(2.9M)(1.8M)(1.9M)
Acquisitions (Net)0400K0100K0
Purchases of Investments(1.74B)(886.4M)(956.3M)(652.1M)(354.2M)
Sales of Investments435.7M1.14B1.16B688.5M763.7M
Other Investing Activities0(400K)000
Investing Cash Flow(1.31B)242.8M203.5M34.7M407.6M
Debt Repayment000(400K)(200K)
Common Stock Issued264.6M4.7M387.2M8.3M700K
Common Stock Repurchased0000(91.9M)
Dividends Paid00000
Other Financing Activities14M0000
Financing Cash Flow278.6M4.7M374.7M7.9M(91.4M)
Effect of Forex Changes00000
Net Change in Cash(475.6M)(26M)230.4M(216.7M)42.4M
Free Cash Flow554.7M(280.3M)(350.7M)(261.1M)(275.7M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$80.8M
+ D&A$5.2M
+ Stock-Based Comp$44.0M
+ Deferred Tax$0
- Working Capital-$233.7M
- Other Non-Cash-$8.5M
= Operating Cash Flow-$273.8M
- Capex-$1.9M
= Free Cash Flow-$275.7M

Analysis

FY2025 free cash flow is -$275.7M. FCF conversion is 341.2% of net income. Operating cash flow was -$273.8M, with capex of -$1.9M. The largest bridge item is Working Capital at -$233.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 9, 2026
10-QQuarterly reportNov 3, 2026
S-3S-3 filingNov 3, 2026
8-KCurrent reportNov 3, 2026
S-8S-8 filingSep 28, 2026

Does ARVN generate free cash flow?

Arvinas, Inc. (ARVN) generated -$275.70M of free cash flow in fiscal 2025.

How much operating cash flow does ARVN produce?

Operating cash flow was -$273.80M, before capital expenditures of $1.90M.